India, Oct. 27 -- Merck & Co., Inc. (MRK) announced positive results from the Phase 3 KEYNOTE-C93 trial, evaluating KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, as monotherapy for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence after receiving prior adjuvant therapy.
According to the company, KEYTRUDA monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS), reducing the risk of disease progression or death by 43% compared with platinum-doublet chemotherapy.
After a median follow-up of 36.7 months, me...